LIBERTY AND JUSTICE FOR ALL

U

Search

Many Voices, One Freedom: United in the 1st Amendment

March 28, 2024

M

Menu

!

Menu

Your Source for Free Speech, Talk Radio, Podcasts, and News.

Print Friendly, PDF & Email

Novavax’s two-dose Covid-19 vaccine for adults ages 18 and older cleared a key step on the path toward Food and Drug Administration emergency use authorization this week. The FDA’s committee of independent vaccine experts voted 21 to 0 with one abstention at the end of an all-day meeting to recommend authorizing the two-dose series of 5 mcg dosing.

Novavax is based on protein technology with purified Spike protein in a matrix 5 mcg per dose. The technology differs from Pfizer and Moderna’s shots, which were the first ones using messenger RNA technology to receive FDA approval and have resulted in catastrophic rates of injury, disability, and death. In the Novavax clinical trial experience, there were no hospitalizations or deaths due to COVID-19, and the overall number of deaths was similar between the groups. Novavax fairly reported several cases of myocarditis and blood clots caused by the vaccine.

Importantly, the briefing booklet indicated that the data are old, and they tested Novavax against extinct variants of the virus, and thus we do not know if the product will work against Omicron or its subvariants.1 Protection against “severe disease” with Omicron is purely speculative and is not expected given the failures of Pfizer, Moderna, JNJ, and AstraZeneca against Omicron.

Novavax’s vaccine would potentially appeal to unimmunized people who have not had COVID-19 and who would prefer a potentially safer product that is not based on the mRNA technology used by Pfizer and Moderna. Though Johnson & Johnson’s shot is also available, the CDC has restricted its use due to a risk of blood clots, primarily in women, and thus JNJ is infrequently utilized. 

As with all the products, according to their clinical trials, they are only meant for people who have not had COVID-19 respiratory illness and should not be used in COVID-19 recovered patients since they were excluded from the clinical trials because of lack of expected benefit and the anticipation of harm. 

On this week’s show, we have a Monkeypox update, music from Joseph Langham’s “Inside these Bodies,”2 and on the backside, an exploratory interview with Dr. Michael Boehmer, PharmD,3 and Dr. Salaheldin Halasa4 on methylene blue and photodynamic therapy as a local virucidal approach in the oral and nasal cavity. We will also explore extracorporal and systemic uses of methylene blue in a futuristic manner for COVID-19 and other illnesses.

So let’s get real, let’s get loud; on America Out Loud Talk Radio, this is The McCullough Report!

The McCullough Report: Sat/Sun 2 PM ET Encore 7 PM – Internationally recognized Dr. Peter A. McCullough, known for his iconic views on the state of medical truth in America and around the globe, pierces through the thin veil of mainstream media stories that skirt the significant issues and provide no tractable basis for durable insight. Listen on iHeart Radio, our world-class media player, or our free apps on AppleAndroid, or Alexa. Each episode goes to major podcast networks early in the week and can be heard on-demand anywhere in the world.

References:

1 https://www.fda.gov/media/158912/download
2 https://music.apple.com/us/album/some-new-sky/128672953?i=128673016
3 https://www.linkedin.com/in/mike-boehmer-15ba1817/
4 https://www.bostonbiolife.com/wp-content/uploads/2018/09/SalaheldinHalasa_Bio.pdf

AMERICA OUT LOUD PODCAST NETWORK
AMERICA OUT LOUD PODCAST NETWORK

America Out Loud is the premier news network with a diverse array of talk shows that inform and inspire. A daily resource for smart people.

  • Dr. Peter McCullough

    Dr. McCullough is an internist, cardiologist, and epidemiologist managing the cardiovascular complications of both the viral infection and the injuries developing after the COVID-19 vaccine in Dallas, TX, USA. Since the outset of the pandemic, Dr. McCullough has been a leader in the medical response to the COVID-19 disaster and has published “Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection,” the first synthesis of sequenced multidrug treatment of ambulatory patients infected with SARS-CoV-2 in the American Journal of Medicine and subsequently updated in Reviews in Cardiovascular Medicine. He has dozens of peer-reviewed publications on the infection and has extensively commented on the medical response to the COVID-19 crisis in TheHill, America Out Loud, NewsMax, One America News, Victory Channel, NTD, and FOX NEWS Channel. Dr. McCullough has testified on pandemic response multiple times in the US Senate, Texas Senate Committee on Health and Human Services, Arizona Senate, Colorado General Assembly, New Hampshire Senate, Pennsylvania Senate, and South Carolina Senate. On December 7, 2022, Dr. McCullough co-moderated a Senate Panel and concluded that all COVID-19 vaccines should be removed from the market for excess mortality. Dr. McCullough has reviewed thousands of reports, participated in scientific congresses, group discussions, and press releases, and has been considered among the world's top experts on COVID-19.

MANY VOICES, ONE FREEDOM: UNITED IN THE 1ST AMENDMENT

Join our community: Your insights matter. Contribute to the diversity of thoughts and ideas.

Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments

Sitewide Newsfeed

More Stories
.pp-sub-widget {display:none;} .walk-through-history {display:none;} .powerpress_links {display:none;} .powerpress_embed_box {display:none;}
Share via
Copy link